ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years
Donald E. Mager
Matched on ORCID iD 0000-0002-4848-0440; OpenAlex author ID A5012352119; NIH RePORTER profile ID 8232623. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 15
2020: 2 papers, 1 grant · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 5
- Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models. Co-author DOI 10.1016/j.xphs.2023.10.019↗
- FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures. Co-author DOI 10.1208/s12248-022-00752-8↗
- Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. Co-author DOI 10.1124/jpet.120.000412↗
- Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant… Co-author DOI 10.1038/s41416-020-01046-6↗
- Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells. Co-author DOI 10.1186/s12885-020-07398-9↗
Grants 1
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Robert M. Straubinger · 5 shared papers, 1 shared grant, 2020–2024 · strength 1.20
- Grant Large-scale proteome-wide analysis with high accuracy/precision to guide pancreatic cancer therapy development R21CA234775↗
- Paper Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuxi… DOI 10.1016/j.xphs.2023.10.019↗
- Paper Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cance… DOI 10.1124/jpet.120.000412↗
- Jun Qu · 1 shared grant, 2020 · strength 0.38
- Jun Wang · 2 shared papers, 2020–2024 · strength 0.37
- Paper Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuxi… DOI 10.1016/j.xphs.2023.10.019↗
- Paper Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate … DOI 10.1038/s41416-020-01046-6↗
- Jin Niu · 2 shared papers, 2020–2022 · strength 0.30
- Qingxiang Lin · 1 shared paper, 2021 · strength 0.16
- William J. Jusko · 1 shared paper, 2021 · strength 0.16
- Wen Wee Ma · 1 shared paper, 2021 · strength 0.16
- Taylor J. Allen-Coyle · 1 shared paper, 2022 · strength 0.15
- Sandra Roche · 1 shared paper, 2022 · strength 0.15
- Finbarr O’Sullivan · 1 shared paper, 2022 · strength 0.15
- Martin M. Clynes · 1 shared paper, 2022 · strength 0.15
- Jun Qu · 1 shared paper, 2020 · strength 0.15
- Xue Wang · 1 shared paper, 2020 · strength 0.15
- Michelle K. Greene · 1 shared paper, 2020 · strength 0.09
- Christopher J. Scott · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.